Corcept Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Mar '26 Mar 31, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	769.1	761.41	675.04	482.38	401.86	365.98
Revenue Growth (YoY)	12.20%	12.79%	39.94%	20.04%	9.80%	3.42%
Cost of Revenue	13.46	12.98	10.88	6.48	5.39	5.28
Gross Profit	755.64	748.43	664.16	475.89	396.47	360.7
Selling, General & Admin	503.42	448.73	280.32	184.26	152.85	122.36
Research & Development	260.44	254.91	246.89	184.35	130.99	113.86
Other Operating Expenses	-	-	-	-	28	-
Total Operating Expenses	763.86	703.63	527.21	368.61	311.84	236.22
Operating Income	-8.22	44.8	136.95	107.28	112.63	124.48
Interest Income	20.35	21.67	24.54	17.28	3.56	0.53
Total Non-Operating Income (Expense)	20.35	21.67	24.54	17.28	3.56	0.53
Pretax Income	12.13	66.46	161.49	124.56	116.19	125.01
Provision for Income Taxes	-35.21	-33.19	20.28	18.42	14.77	12.49
Net Income	46.67	98.17	139.73	105.5	101.29	112.51
Net Income to Common	46.67	98.17	139.73	105.5	101.29	112.51
Net Income Growth	-64.77%	-29.74%	32.45%	4.15%	-9.98%	6.13%
Shares Outstanding (Basic)	104	104	103	104	107	116
Shares Outstanding (Diluted)	116	120	113	112	116	126
Shares Change (YoY)	0.21%	5.73%	1.55%	-3.64%	-7.94%	1.42%
EPS (Basic)	0.45	0.95	1.35	1.02	0.95	0.97
EPS (Diluted)	0.35	0.82	1.23	0.94	0.87	0.89
EPS Growth	-69.83%	-33.33%	30.85%	8.05%	-2.25%	4.71%
Shares Outstanding	106.37	105.97	105.11	103.41	107.84	105.94
Free Cash Flow	119.79	141.79	196.12	126.54	119.91	167.42
Free Cash Flow Growth	-15.51%	-27.71%	54.99%	5.53%	-28.38%	11.07%
Free Cash Flow Per Share	1.03	1.18	1.73	1.13	1.03	1.33
Gross Margin	98.25%	98.30%	98.39%	98.66%	98.66%	98.56%
Operating Margin	-1.07%	5.88%	20.29%	22.24%	28.03%	34.01%
Profit Margin	6.16%	13.09%	20.92%	22.00%	25.24%	30.74%
FCF Margin	15.58%	18.62%	29.05%	26.23%	29.84%	45.75%
EBITDA	-6.76	45.95	137.75	108.32	113.89	125.96
EBITDA Margin	-0.88%	6.03%	20.41%	22.46%	28.34%	34.42%
EBIT	-8.22	44.8	136.95	107.28	112.63	124.48
EBIT Margin	-1.07%	5.88%	20.29%	22.24%	28.03%	34.01%
Effective Tax Rate	-290.31%	-49.94%	12.56%	14.79%	12.71%	9.99%

Updated Apr 30, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q